Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    63,634.03
    +45.72 (+0.07%)
     

  • CMC Crypto 200

    1,379.72
    +67.10 (+5.11%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • Dow

    37,986.40
    +211.02 (+0.56%)
     

  • Nasdaq

    15,282.01
    -319.49 (-2.05%)
     

  • Gold

    2,406.70
    +8.70 (+0.36%)
     

  • Crude Oil

    83.24
    +0.51 (+0.62%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Here's Why AnaptysBio, Inc. Stock Surged on Wednesday

Cory Renauer, The Motley Fool
Updated

What happened

Shares of AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company, rose 11.1% in midday trading on Wednesday before locking in a 9.4% gain to end the day. Investors appear excited about a recently announced engagement at the annual meeting of the American Academy of Dermatology.

So what

On Saturday, Feb. 17, AnaptysBio will present data from a phase 2a atopic dermatitis (eczema) trial involving the most advanced candidate the company owns outright, ANB020. The novel new drug candidate inhibits interleukin-33 (IL-33), a mediator of skin-related disorders.

Finger drawing an upward sloping chart in the air.
Finger drawing an upward sloping chart in the air.

Image source: Getty Images.

ADVERTISEMENT

Since IL-33 acts upstream of IL-4 and IL-13, two proteins inhibited by Dupixent, there's a chance ANB020 could be far more effective at stopping inflammation than the recently launched drug. Dupixent is expected to generate peak annual sales exceeding $4 billion for partners Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN).

Now what

AnaptysBio didn't reveal much in its release, but investors can probably look forward to positive data. The company plans to begin a big multi-center trial with between 200 and 300 eczema patients in the first half of the year. Beyond eczema, ANB020 is also in midstage trials for peanut allergies and eosinophilic asthma, both of which should read out in the first half as well.

While AnaptysBio funds development of ANB020 on its own, Tesaro (NASDAQ: TSRO) will fund a phase 3 ovarian-cancer trial with big implications for AnaptysBio. The study, slated to begin in the first half, will test Zejula in combination with TSR-042, a checkpoint inhibitor candidate Tesaro licensed from AnaptysBio.

More From The Motley Fool

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy.